吸入TD139靶向抑制Galectin-3治疗特发性肺纤维化
这项随机、双盲、多中心、安慰剂对照的1/2a期研究评估了吸入TD139在36名健康受试者和24名IPF患者中的安全性、耐受性、药代动力学和药效学。结果表明吸入TD139安全且耐受良好,能抑制肺泡巨噬细胞Gal-3表达并降低与IPF进展相关的血浆生物标志物。
要点
- 吸入TD139在健康受试者和IPF患者中安全且耐受良好。
- TD139可浓度依赖性抑制肺泡巨噬细胞Gal-3表达。
- Gal-3抑制伴随IPF相关血浆生物标志物降低。
核心结论
- 吸入TD139在健康受试者和IPF患者中安全且耐受良好。
- TD139可抑制肺泡灌洗液巨噬细胞Gal-3表达,并降低与IPF进展相关的血浆生物标志物。
研究设计与样本
- 随机、双盲、多中心、安慰剂对照的1/2a期研究。
- 纳入36名健康受试者和24名IPF患者。
- 健康受试者设6个剂量组,每组6人(TD139:安慰剂=4:2),单次给予TD139 0.15-50 mg。
- IPF患者设3个剂量组,每组8人(TD139:安慰剂=5:3),每日一次给予TD139 0.3-10 mg,持续14天。
主要发现
- 吸入TD139耐受良好,无显著治疗相关副作用。
- TD139迅速吸收,平均达峰时间(C max)为0.6至3小时,血浆半衰期(T 1/2)为8小时。
- 肺内TD139浓度比血液高>567倍,全身暴露可预测靶部位暴露。
- 与安慰剂相比,3 mg和10 mg剂量组肺泡巨噬细胞Gal-3表达降低,呈浓度依赖性抑制。
- 肺内Gal-3抑制与血浆中PDGF-BB、PAI-1、Gal-3、CCL18和YKL-40降低相关。
临床怎么用
- 吸入TD139可能作为IPF的潜在靶向治疗,需进一步开展疗效验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Galectin (Gal)-3 is a profibrotic β-galactoside-binding lectin that plays a key role in the pathogenesis of idiopathic pulmonary fibrosis (IPF) and IPF exacerbations. TD139 is a novel and potent small-molecule inhibitor of Gal-3.A randomised, double-blind, multicentre, placebo-controlled, phase 1/2a study was conducted to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled TD139 in 36 healthy subjects and 24 patients with IPF. Six dose cohorts of six healthy subjects were evaluated (4:2 TD139:placebo ratio) with single doses of TD139 (0.15-50 mg) and three dose cohorts of eight patients with IPF (5:3 TD139:placebo ratio) with once-daily doses of TD139 (0.3-10 mg) for 14 days.Inhaled TD139 was well tolerated with no significant treatment-related side-effects. TD139 was rapidly absorbed, with mean time taken to reach maximum plasma concentration (C max) values ranging from 0.6 to 3 h and a plasma half-life (T 1/2) of 8 h. The concentration of TD139 in the lung was >567-fold higher than in the blood, with systemic exposure predicting exposure in the target compartment. Gal-3 expression on alveolar macrophages was reduced in the 3 and 10 mg dose groups compared with placebo, with a concentration-dependent inhibition demonstrated. Inhibition of Gal-3 expression in the lung was associated with reductions in plasma biomarkers centrally relevant to IPF pathobiology (platelet-derived growth factor-BB, plasminogen activator inhibitor-1, Gal-3, CCL18 and YKL-40).TD139 is safe and well tolerated in healthy subjects and IPF patients. It was shown to suppress Gal-3 expression on bronchoalveolar lavage macrophages and, in a concerted fashion, decrease plasma biomarkers associated with IPF progression.
引用
- Hirani N, MacKinnon AC, Nicol L, et al. Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2021. PMID: 33214209. doi:10.1183/13993003.02559-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。